Industry Blog

Simcere Pharma Q3 Profit Plunges On Higher Expenses - Update

Chinese drug manufacturer Simcere Pharmaceutical Group (SCR: News ) Monday reported a 82% decline in net income for the third quarter, impacted negatively by higher expenses.

Net income for the quarter attributable to the company was RMB 16.43 million or RMB 0.14 per share, much lower than RMB 91.16 million or RMB 0.72 per share in the prior-year quarter. In US dollars, net income attributable to Simcere was $2.41 million or $0.02 per share for the most recent quarter.

Earnings per American depository shares, or ADS, plunged to RMB 0.29, or US$0.04, from RMB 1.44 in the year-ago quarter.

On an average, four analysts polled by Thomson Reuters expected earnings of US$0.09 per share for the quarter. Analysts’ estimates typically exclude special items.

Total third-quarter revenues increased slightly to RMB 443.7 million or US$65.0 million from RMB 443.4 million a year earlier. Analysts estimated revenues of US$69.09 million for the quarter.

Commenting on the results, Jinsheng Ren, chairman and chief executive officer, said, “Our sales and gross profit margins remained stable this quarter. However, lower sales in Endu, impacted by the restructuring of the sales team, and an increase in sales and marketing expenses for new to market drugs like Anxin and Sinofuan, caused a significant decrease in operating income.”

Product revenues slipped to RMB 439.02 million from RMB 441.21 million in the prior-year quarter. Within this, revenues from Endu, Simcere’s patented anti-cancer biotech product, amounted to RMB 21.6 million, or US$3.2 million, down 60.2% from RMB 54.4 million for the same period in 2008.

 Source: rttnews.com

China Aoxing Pharmaceutical Company to Present at Brean Murray, Carret & Co. 2009 China Growth Conference

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) (”China Aoxing”), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will present at the 2009 China Growth Conference held by Brean Murray, Carret & Co. at the The Millennium Broadway Hotel in New York City, on November 19, 2009.

The Company will update the Company business including product portfolio, development pipeline, financial highlights and its long-term growth strategies.

For further details, please contact your institutional sales representative.

Source: CNN.Money.Com

China shares at 3 week low..

HSI range-bound, off 13-month high hit last week

* Sinopharm up 15.8 pct, but market starts discounting rally

 * U.S. Fed expected to keep policy rate steady (Updates to close)

 By Claire Zhang and Nerilyn Tenorio

 SHANGHAI/HONG KONG, Sept 23 (Reuters) - Chinese shares closed lower on Wednesday as the mainland markets remained weighed down by worries over excessive IPO share supply while Hong Kong began to discount the listing debut gains made by Sinopharm (1099.HK).
The markets, which also started factoring in expectations of stable monetary policies by both the United States and China, will be in search of new catalysts for their next trading move.
“People (on Wall Street) are still cautious, and here we would just follow that trading stance. We won’t be seeing very aggressive trading moves,” said Alex Wong, director at Ample Finance Group in Hong Kong.

 In Shanghai, traders have started taking profit ahead of the week-long Chinese national holiday from Oct 1.
China’s top pharmaceutical firm Sinopharm debuted in a consolidating Hong Kong market with a 15.8 percent closing gain, which analysts said was relatively modest compared with China’s other recent new listings.
Hong Kong’s benchmark Hang Seng Index .HSI settled 0.49 percent lower at 21,595.52 points, slipping off the 13-month closing high at the 21,700-level hit last week.
Turnover was HK$58.5 billion ($7.5 billion), up from Tuesday’s HK$50 billion.
The China Enterprises Index .HSCE of top locally listed mainland Chinese stocks was down 0.6 percent at 12,431.81.
Banks and financials were down 1.1 percent, with index heavyweight HSBC (0005.HK) down 1 percent at HK$90.80, China’s leading lender ICBC (1398.HK) down 0.82 percent at HK$6.06, and Bank of China (3988.HK) down 1.15 percent at HK$4.28.
Sinopharm Group Co Ltd, which raised $1.13 billion in its IPO, jumped to as high as HK$19.74, or 23.4 percent above its HK$16 issue price, before closing up 15.8 percent at HK$18.52.
Geely Automobile Holdings (0175.HK), China’s largest privately-owned carmaker, was up nearly 19 percent at HK$2.13, easing back from a 25.7 percent initial gain after the lifting of trading suspension. The carmaker said earlier that it planned to issue HK$2.59 billion ($334 million) in convertible bonds and warrants to an affiliate of Goldman Sachs (GS.N) [ID:nHKG310894].

 www.reuters.com

Pharmaceutical giants eye China’s booming market

China’s ambitious $124-billion effort to provide basic health coverage for the vast majority of its 1.3 billion citizens by 2011 is a brimming opportunity for global pharmaceutical companies.

As growth in the US and European markets remains sluggish, many giant pharmaceutical companies are expanding their sales forces, distribution channels and research operations in China to tap into the country’s robust drug market.

China’s drug market is expected to grow about 22 percent annually over the next five years, said Mandy Chui, senior principal of (Intercontinental Marketing Services) IMS Health Inc.

Chui is the China expert at IMS Health, which provides market data on the pharmaceutical and healthcare industries.

“We see companies continuing to invest in China because the other markets are not growing,” Chui said. “For companies, (China’s growth) is certainly a good story to tell to Wall Street, right?”

With a huge and aging population, rapid urbanization and adoption of Western lifestyles that give rise to hypertension, obesity and other diseases, China is poised to become the world’s third-biggest pharmaceutical market by 2013, up from its current No 5 spot, said Chui.

The $24.5-billion market is expected to swell to betweem $68 billion and $78 billion by 2013, Chui said, leaving it behind only the US and Japan.

“China is taking over from Germany and France,” she said.

“It’s like a big wake-up call. If they (big pharmaceutical companies) are not in there at this point in time, all of them are not going to grow,” Chui said.

In the race to penetrate the Chinese market, she said European drug makers such as Bayer AG, AstraZeneca PLC and Sanofi-Aventis SA have taken the lead.

www.chinadaily.com.cn

China admits its companies’ involvement in fake drugs case

China has admitted that its pharmaceutical companies were involved in shipping fake drugs labeled ‘Made In India’ to Nigeria.

“The Chinese authorities have accepted this position (that its firms were involved in the case),” an official said.

“The Indian government took up the matter with the Nigerian authorities and on further probe, it was found that the drugs had actually originated in China and not in India,” he added.

In June, Nigeria’s drug regulatory authority National Agency for Food And Drug Administration And Control (NAFDAC) had reported about the detention of a large consignment of fake anti-malarial generic pharmaceuticals labeled ‘Made in India’ which were actually produced in China.

Following the incident, India took up the issue with China fearing that this could damage the reputation of the 12-billion-dollar Indian pharmaceutical industry in the global market.

www.ptinews.com

Company targets China for overseas growth

Dundonald-based pharmaceutical manufacturing firm Sepha will be heading to China for the first time later this year as part of its bid to win new business in overseas markets.

 

The company, which makes inspection equipment to test the seals of pharmaceutical and medical device blister packs and other specialist products, has already shown its machines in Japan and Mexico this summer.

The firm will also be returning to India in the autumn.

The company currently employs 18 people and three executive directors and its customers already include some of the world’s biggest pharmaceutical companies.

Its turnover has increased 60% since management bought it out with the help of private equity firm Enterprise Equity in 2005, the company said.

Enterprise Equity is one of Northern Ireland’s longest established private equity businesses. It has invested over £27m in around 40 firms since its formation in 1987 in a broad spectrum of sectors. Other firms in its portfolio include Balcas, Kelsius and BCO Technologies. Sepha has made some headway in Japan with the help of an Invest NI-Enterprise Ireland service that offers on-the-ground translator services and helps develop sales leads.

www.belfasttelegraph.co.uk

Tag Cloud